300026.SZ
红日药业
SZSE · Healthcare · C 制造业 · CN
CNY 3.33
−2.06%Year over year
Reported trailing growth
- Revenue
- -18.1%
- EBITDA
- —
- EBIT
- +192.5%
- EPS
- +45.7%
- Free cash flow
- +8.7%
- Operating cash flow
- -2.4%
Forward estimates
Based on analyst estimates
- Revenue
- -78.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -9.4%
- EBITDA
- -25.3%
- EBIT
- -47.3%
- Net income
- -69.1%
- EPS
- -63.8%
- Free cash flow
- -24.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026